Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) fell 32.7% on Friday . The stock traded as low as $1.01 and last traded at $1.01. 2,700 shares were traded during mid-day trading, an increase of 50% from the average session volume of 1,800 shares. The stock had previously closed at $1.50.
Silence Therapeutics Stock Performance
The business has a 50 day simple moving average of $2.63 and a 200-day simple moving average of $5.15.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Recommended Stories
- Five stocks we like better than Silence Therapeutics
- Consumer Staples Stocks, Explained
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 5 Top Rated Dividend Stocks to Consider
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
